brinzolamide + timolol




Firma Chun Cheong
Concise Prescribing Info
Brinzolamide 1%, timolol (as maleate) 0.5%
Reduction of IOP in adult patients w/ open-angle glaucoma or ocular HTN for whom monotherapy is insufficient.
Dosage/Direction for Use
Hypersensitivity to brinzolamide & timolol, other β-blockers, or to sulphonamides. Bronchial asthma, severe COPD. Sinus bradycardia, sick sinus syndrome, SA block, 2nd or 3rd degree AV block not controlled w/ pace-maker, overt cardiac failure, cardiogenic shock. Severe allergic rhinitis. Hyperchloraemic acidosis. Severe renal impairment.
Special Precautions
Patients w/ severe peripheral circulatory disturbance/disorders; pseudoexfoliative glaucoma or pigmentary glaucoma. Choroidal detachment. Not recommended in patients w/ narrow-angle glaucoma. Concomitant use w/ other systemic β-blockers or carbonic anhydrase inhibitors. Contains benzalkonium Cl. Severe hepatic impairment. Temporary blurred vision or other visual disturbances may affect ability to drive or use machines. Pregnancy & lactation. Childn ≤18 yr. Timolol: Patients w/ CV diseases & hypotension; 1st degree heart block; mild/moderate COPD; history of atopy or a history of severe anaphylactic reaction to a variety of allergens. May mask signs of hyperthyroidism & signs & symptoms of acute hypoglycaemia. Muscle weakness. May block systemic β-agonist effects of adrenaline. May induce dryness of eyes. Brinzolamide: Acid/base disturbances. Patients w/ risk of renal impairment. May impair mental alertness. May affect corneal hydration.
Adverse Reactions
Blurred vision, eye pain & irritation, punctuate keratitis; dysgeusia; decreased heart rate.
Drug Interactions
Timolol: Potential for additive effect w/ oral Ca channel blockers, β-adrenergic blocking agents, antiarrhythmics (including amiodarone), digitalis glycosides, parasympathomimetics, guanethidine. Decreased response to adrenaline. Potentiated hypertensive reaction to sudden w/drawal of clonidine. Potentiated systemic β-blockade w/ CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine). Increased hypoglycaemic effect of antidiabetic agents. Mydriasis w/ adrenaline. Brinzolamide: Potential for additive effect w/ oral carbonic anhydrase inhibitor. Inhibited metabolism w/ CYP3A4 inhibitors eg, ketoconazole, itraconazole, clotrimazole, ritonavir & troleandomycin.
ATC Classification
S01ED51 - timolol, combinations ; Belongs to the class of beta blocking agents. Used in the treatment of glaucoma.
Azarga eye drops
(bottle) 5 mL x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in